Cerebras Raises IPO Range to $150-160: 20x Demand

Cerebras Systems lifted the price range on its IPO to $150 to $160 a share ahead of pricing, up from the initial $115 to $125 range filed in early May, after orders ran more than 20 times the available shares. At the high end the deal raises up to $4.8 billion and values the wafer-scale AI chipmaker at up to $48.8 billion fully diluted — a roughly 84% jump from the $26.6 billion implied at the original midpoint.

The bump is the headline. The math underneath is the story.

Cerebras printed $510 million in 2025 revenue with a 47% reported net margin (on an accounting basis that included non-recurring gains) and a GAAP operating loss of roughly $146 million. At $48.8 billion, the deal is pricing at approximately 96x trailing sales — a multiple that requires the company to compound revenue at greater than 70% per year for the next three years just to grow into a 25x sales figure that resembles peer infrastructure software.

What changed between the original filing and the bump

The early-May S-1/A filed with the SEC first set the range at $115-$125 with 28 million Class A shares offered. CNBC then reported the bump to $150-$160 late in the cycle after the underwriter book — led by Morgan Stanley, Citigroup, Barclays and UBS — closed at greater than 20 times oversubscribed. At the top of the new range the implied valuation could reach $48.8 billion fully diluted, with up to $4.8 billion in gross proceeds.

That is a roughly 28% increase in offer price while share count stayed flat at 28 million. The reflexive read is that demand simply pulled the price higher; the more useful read is that the lead syndicate now believes the post-IPO float is positioned to clear higher even after lockup-window dilution. Cerebras’ Class A structure plus warrant overhang from earlier financing rounds mean the public float is materially smaller than the diluted share count suggests — a structural underwrite for early after-market support.

The 96x sales multiple in context

At ~$48.8 billion versus $510 million revenue:

• Nvidia trades at roughly 25x forward sales — the bull-case multiple for the entire AI-chip cohort.
• Palantir trades around 45x forward sales — already a stretched outlier (see the Palantir AI-revenue audit on whether the multiple is defensible).
• Astera Labs, the closest AI-infrastructure pure-play, trades near 35x forward sales.

96x trailing is not 96x forward — Cerebras’ 2026 revenue trajectory could compress the multiple meaningfully if the OpenAI buildout converts on schedule. But “compress meaningfully” still leaves the stock at roughly 40-50x forward sales in the bull case. The pricing requires both flawless OpenAI ramp execution AND a sustained AI capex cycle through 2028 — neither of which is in the underwriter’s hands once the lockup unwinds.

OpenAI is the entire growth thesis

Cerebras’ anchor commercial relationship is OpenAI’s 750-megawatt low-latency compute commitment through 2028, valued at more than $20 billion across the multi-year window. The deal includes a $1 billion working-capital loan tied to delivery milestones, which means OpenAI is not only a customer — it is effectively financing Cerebras’ inventory ramp.

Two things follow from that structure:

1. Concentration risk is severe. A material slip in OpenAI’s own capex cadence — driven by Stargate funding gaps, Microsoft partnership friction, or a shift toward in-house silicon at the buyer — flows directly into Cerebras’ top line with no diversification cushion. The same hyperscaler capex story is already pulling memory suppliers into a record pricing cycle, but Micron has dozens of HBM customers spread across Nvidia, AMD, and the hyperscalers; Cerebras has effectively one anchor.
2. AWS distribution provides some optionality — Cerebras CS-3 systems are deploying into AWS data centers and via Amazon Bedrock — but AWS has not disclosed a committed dollar volume comparable to the OpenAI tranche schedule.

The implied math: if OpenAI accounts for 70%+ of FY26 revenue (a reasonable inference from the multi-tranche delivery schedule), then a single-customer pause has a multiple-compressing impact on the stock that no AI-infrastructure peer faces in the same severity.

The cohort signal: AI-hardware IPOs are pricing at extreme multiples

Cerebras is the largest of three high-profile AI-infrastructure IPOs queued for spring 2026. The bigger story is cohort multiple expansion:

• The original range implied $26.6 billion at 52x sales — already premium versus 2023-2024 chip IPO comps.
• The new range implies $48.8 billion at 96x sales — closer to 2021 SPAC-era pricing than to traditional chip IPO discipline.

For investors holding Nvidia, Broadcom, AMD, or other AI-cohort names at 25-30x forward, the Cerebras print is the multiple ceiling that justifies (or breaks) the bull case for the entire AI-hardware cohort. A successful pricing at $160 plus a 30%+ first-week pop sustains the cohort’s premium. A break-issue with a 20%+ giveback would compress comparable multiples across the sector within days.

What to watch from here

Three checkpoints around the IPO pricing:

1. Final price + first-day allocation tier — whether shares hit institutional accounts or retain a retail-heavy book determines lockup-window volatility.
2. OpenAI capex commentary in the next round of Microsoft and Oracle hyperscaler earnings — those reveal whether the buyer’s underlying capex curve is intact.
3. Q1 FY26 revenue print from Cerebras post-listing — the cleanest test of whether the OpenAI tranche schedule converted on plan.

The pre-bump Cerebras IPO walkthrough covers the wafer-scale architecture, the second-attempt narrative, and the operating-loss-versus-net-income reconciliation. The bump shifts the question from “is the company real?” — settled at $510M revenue with hyperscaler validation — to “does the public-market multiple price the customer concentration AND the FY27 execution risk?” That one is still open.

Editor’s risk note: Editorial analysis, not investment advice. IPO pricing is volatile by design — final terms, allocation tiers, and post-listing lockups all materially change the risk profile from what is described above. Verify current filings and consult a qualified advisor before trading.